Morphosys Ag

Novartis Ag

Immatics Biotechnologies Gmbh

Universitaetsklinikum Tuebingen

Alexandra Kraus

Klaus Felix Hartlepp

Toni Weinschenk

Andrea Mahr

Claudia Wagner

Dominik Maurer

Scott Glaser

Michael Tesar

Alisa K Waterman

Jian Shi

Tobias Litzenburger

Michael DiDonato

Sarah Rue

Christian Cho-Hua Lee

Anna Galkin

Xenia Karola Wezler

Yong Jia

Daniel Rajotte

Christoph Erkel

Christoph Michael Ernst

Andreas Paul Peschel

Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

ENTPD2 antibodies, combination therapies, and methods of using the antibodies and combination therapies

The present invention relates to antibodies or fragments thereof binding to human WT1/HLA. In particular, the present invention relates to antibodies or fragments thereof that have combined improved and/or beneficial properties, and are therefore suited for clinical development.

Anti-WT1/HLA-specific antibodies

This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.

Anti-staphylococcal antibodies

Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.

Antibodies for guanylyl cyclase receptors

Growing community of inventors

Munich, Germany

Alexandra Kraus